In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d

Q: What does this research mean for the field?

Tirofiban increases the rate of excellent functional outcomes at 90 days compared to placebo in acute ischemic stroke patients who have an inadequate response to tenecteplase. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Zaid Alsaaran; Michael D. Hill

doi:10.7326/annals-26-03132-jc

August 31, 2026Annals of Internal Medicine

In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d

View at Publisher

Ask AI

Bookmark

Share

Key Points

Determine whether tirofiban improves 90-day functional outcomes compared with placebo in acute ischemic stroke patients with an inadequate response to tenecteplase.
Randomized trial evaluating intravenous tirofiban versus placebo in acute ischemic stroke patients who exhibited inadequate early response to tenecteplase thrombolysis.
Follow-up assessed functional outcomes at 90 days.
Tirofiban significantly increased the rate of excellent functional outcomes at 90 days compared with placebo.
Specific event rates, effect sizes, confidence intervals, and p-values were omitted in the abstract.

Implication

Randomized trial demonstrates higher 90-day excellent functional outcome rates with tirofiban in acute ischemic stroke unresponsive to tenecteplase, indicating a viable rescue strategy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alsaaran et al. (2026) studied this question.

synapsesocial.com/papers/6a993503636c6408cfa7cd14 https://doi.org/10.7326/annals-26-03132-jc

View at Publisher

Ask AI

Bookmark

Share

In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d

Key Points

Implication

Abstract

Discussion

Cite This Study

In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Annals of Internal Medicine

Keep reading

More related papers

More from Annals of Internal Medicine